This legal opinion addresses the adjustment of the exercise price for the stock appreciation rights incentive plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd. Key decisions include the approval of the plan by the company’s board and relevant authorities. The adjustments are set to align with the company's financial strategies and regulatory requirements.
Summary generated by AI · Always verify with source document
To: Chengdu Kanghong Pharmaceutical Group Co., Ltd.
This legal opinion is issued based on the authorization of the company’s board and relevant regulatory documents, regarding the adjustment of the exercise price for the stock appreciation rights incentive plan for 2023.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.